The EU has expanded the label for the use of GSK/Innoviva's slow-stop pulmonary inhalers

The European Commission has expanded glaxoSmithKline/Innoviva's once-a-day Trelegy Ellipta label to make it the first single-inhaled triple therapy for patients with moderate to severe slow-blocking lungs (LCPs), who are treated with corticosteroids (ICS) and long-acting β-excited agents (LABA) without double bronchid dilation or inhalation.
, GlaxoSmithKline noted that while bronchal dilation is considered the basis for slow-blocking lung therapy, "many patients may continue to struggle with symptoms and deterioration over time."
Trelegy Ellipta's expanded adaptive disorder "reflects evidence supporting its potential benefits in a wider patient population, rather than the initial explanation that gives them the option of taking a single inhalation triple therapy once a day," the company added.
label update is based on data from the landmark SLOW Lung Therapy PAthway (IMPACT) study, which showed Trelegy Ellipta (fluorotika pinealate / umeclidinium / vilanterol'FF / UMEC / VI') better than ICS / LABA Relvar / Breo Ellipta (FF/VI) and long-acting toxaline-alkali-infested antagonists (LAMA)/LABA Anoro Ellipta (UMEC/VI) are used in patients with moderate to severe chronic obstructive pulmonary disease "to achieve significant endpoints in multiple clinical trials, including reducing acute exacerbation and improving lung function and health-related quality of life".
"We're pleased that a single inhalation triple therapy once a day can now be used for patients with chronic pulmonary resistance who need to strengthen double bronchial dilation, providing them with a new option to help them treat their illness," commented Dr. Paul Meunier, vice president of respiratory medicine at Innoviva.
Trelegy Ellipta was originally approved in the European Union last November as a maintenance treatment for adult patients with moderate to severe OBSTRUCT who were not adequately treated through a combination of ICS and LABA. (This web article)